Salix Pharmaceuticals.

PositionStatewide

RALEIGH -- Drug developer Salix Pharmaceuticals scuttled its $2.7 billion merger with Lainate, Italy-based Cosmo Pharmaceuticals after the federal government toughened rules regarding corporate inversions --companies that reincorporate overseas to take advantage of lower tax rates. The companies had planned to move the headquarters...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT